Hesitancy to Receive the Booster Doses of COVID-19 Vaccine Among Cancer Patients in China: A Multicenter Cross-Sectional Survey - Four PLADs, China, 2022

Cancer patients are more vulnerable and have higher mortality rates from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population; however, coverage for booster doses of the coronavirus disease 2019 (COVID-19) vaccine was low among cancer patients in China. Overall, 3...

Full description

Saved in:
Bibliographic Details
Published in:China CDC weekly 2023-03, Vol.5 (10), p.223-228
Main Authors: Wang, Yuxiao, Zhang, Lei, Chen, Siyu, Lan, Xinquan, Song, Moxi, Su, Rila, Yang, Jianzhou, Wang, Zixin, Xu, Junjie
Format: Article
Language:English
Subjects:
Preplanned Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer patients are more vulnerable and have higher mortality rates from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than the general population; however, coverage for booster doses of the coronavirus disease 2019 (COVID-19) vaccine was low among cancer patients in China. Overall, 32.0% and 56.4% of cancer patients from four Provincial Level Administrative Divisions (PLADs) expressed hesitancy toward the first and second booster doses, respectively. Factors negatively associated with hesitancy to receive booster doses included positive attitudes, perceived support, and higher exposure to COVID-19 vaccination information. Conversely, postvaccination fatigue was positively associated with vaccine hesitancy. Improved COVID-19 vaccination coverage is needed to promote health for cancer patients.
ISSN:2096-7071
2096-7071
DOI:10.46234/ccdcw2023.041